Open AccessCharacteristics of the isocitrate dehydrogenase gene and telomerase reverse transcriptase promoter mutations in gliomas in Chinese patients
Author(s) -
Qu ChongXiao,
Ji HongMing,
Shi XiangCheng,
Bi Hong,
Zhai LiQin,
Han DeWu
Publication year - 2020
Publication title -
brain and behavior
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.915
H-Index - 41
ISSN - 2162-3279
DOI - 10.1002/brb3.1583
Subject(s) - isocitrate dehydrogenase , telomerase reverse transcriptase , telomerase , mutation , idh1 , glioma , cancer research , biology , microbiology and biotechnology , gene , oncology , medicine , genetics , enzyme , biochemistry
Objectives To explore the characteristics of IDH and TERT promoter mutations in gliomas in Chinese patients. Methods A total of 124 Chinese patients with gliomas were enrolled to study the frequencies of mutations in isocitrate dehydrogenase (IDH) and telomerase reverse transcriptase promoter (TERTp). Among the 124 patients, 59 patients were enrolled to study the classification of gliomas based on mutations in IDH and TERTp. Results Isocitrate dehydrogenase mutations are positively correlated with a good prognosis but mutations in TERTp cannot predict prognoses independently. The combined analysis of the mutations of IDH and TERTp can predict the prognosis more accurately. Patients with IDH and TERTp glioma mutations have the best prognosis, followed by only IDH mutation patients and only TERTp mutation patients, which have the worst prognosis. IDH and TERTp mutations occur frequently in males, younger patients or lower‐grade patients. In contrast, only TERTp mutations occur frequently in females, older patients or higher‐grade patients. Conclusions Patients with IDH and TERTp glioma mutations have the best prognosis, and only IDH mutation patients and only TERTp mutation patients have the worst prognosis. Moreover, the molecular classification of gliomas by mutations of IDH and TERTp is not suitable for pediatric patients.